1-20 of 303
Shaji K Kumar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Free
Clinical Trials & Observations
Udit Yadav, Shaji K. Kumar, Linda B. Baughn, Angela Dispenzieri, Patricia Greipp, Rhett Ketterling, Dragan Jevremovic, Francis K. Buadi, David Dingli, Martha Q. Lacy, Rafael Fonseca, P. Leif Bergsagel, Sikander Ailawadhi, Vivek Roy, Ricardo Parrondo, Taimur Sher, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Joselle Cook, Moritz Binder, Eli Muchtar, Rahma Warsame, Taxiarchis V. Kourelis, Ronald S. Go, Yi Lin, Abhishek Seth, Scott C. Lester, William G. Breen, Robert A. Kyle, Morie A. Gertz, S. Vincent Rajkumar, Wilson I. Gonsalves
Journal: Blood
Blood (2023) 142 (22): 1871–1878.
https://doi.org/10.1182/blood.2023021187
Published: 2023
Includes: Supplemental data
Journal Articles

TET2 Down-Regulation Confers Bortezomib Resistance in Multiple Myeloma

Free
Yun Dai, Xiaobo Liu, Ting Yang, Shaji K Kumar, Fengyan Jin
Journal: Blood
Blood (2022) 140 (Supplement 1): 4185–4186.
https://doi.org/10.1182/blood-2022-168239
Published: 2022
Journal Articles

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Free
Eli Muchtar, Surendra Dasari, Martha Grogan, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Taxiarchis Kourelis, Itzhak Z. Attia, Francisco Lopez-Jimenez, Dennis Murphree, Paul A. Friedman, Shaji K Kumar, Angela Dispenzieri
Journal: Blood
Blood (2022) 140 (Supplement 1): 7230–7232.
https://doi.org/10.1182/blood-2022-168119
Published: 2022
Journal Articles

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Free
Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda
Journal: Blood
Blood (2022) 140 (Supplement 1): 7315–7316.
https://doi.org/10.1182/blood-2022-164966
Published: 2022
Journal Articles

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Free
Fengyan Jin, Peiyu Yang, Haimin Chen, Xinyue Liang, Weiling Xu, Shanshan Yu, Wenyang Huang, Xingchen Yi, Qiang Guo, Mengru Tian, Tingting Yue, Mengyao Li, Yingjie Zhang, Mengxue Zhang, Yurong Yan, Zhongli Hu, Shaji K Kumar, Fan Zhou, Yun Dai
Journal: Blood
Blood (2022) 140 (Supplement 1): 4360–4361.
https://doi.org/10.1182/blood-2022-168602
Published: 2022
Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard
Journal: Blood
Blood (2022) 140 (Supplement 1): 1360–1362.
https://doi.org/10.1182/blood-2022-160038
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Free
Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Free
Shaji K Kumar, Betsy Laplant, Erik J Asmus, Francis K. Buadi, Wilson I. Gonsalves, Eli Muchtar, David Dingli, Melanie Ann Thompson, Ronald Go, Rahma M Warsame, Taxiarchis Kourelis, Yi L. Hwa, Amie Fonder, Miriam A. Hobbs, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Nelson Leung, Moritz Binder, S. Vincent Rajkumar, Morie A Gertz, Prashant Kapoor
Journal: Blood
Blood (2022) 140 (Supplement 1): 10142–10143.
https://doi.org/10.1182/blood-2022-169046
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Free
Thierry Facon, Shaji K Kumar, Katja Weisel, Saad Usmani, Philippe Moreau, Torben Plesner, Robert Z. Orlowski, Nizar Jacques Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Robin Carson, Fredrik Borgsten, Hartmut Goldschmidt
Journal: Blood
Blood (2022) 140 (Supplement 1): 10133–10136.
https://doi.org/10.1182/blood-2022-163555
Published: 2022
Journal Articles

Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

Free
Linda B. Baughn, Elizabeth S. Mearns, Michael Nixon, Vivek S. Chopra, Allicia Girvan, R. Frank Cornell, Jayeta Saxena, Bethany M. Slifko, Jordan Clark, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10114–10115.
https://doi.org/10.1182/blood-2022-158076
Published: 2022
Journal Articles

Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma

Free
Neeraj Sharma, Hongwei Tang, Huihuang Yan, Shulan Tian, Suganti Shivaram, Taxiarchis Kourelis, Shaji K Kumar, Linda B. Baughn
Journal: Blood
Blood (2022) 140 (Supplement 1): 4209–4210.
https://doi.org/10.1182/blood-2022-166744
Published: 2022
Journal Articles

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Free
Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4620–4622.
https://doi.org/10.1182/blood-2022-158231
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Free
Shaji K Kumar, Philippe Moreau, Nizar Jacques Bahlis, Thierry Facon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 10150–10153.
https://doi.org/10.1182/blood-2022-163335
Published: 2022
Journal Articles

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Free
Shaji K Kumar, Alfred L. Garfall, Suzanne Trudel, Enrique M. Ocio, Emma Scott, Lin Huang, Xuewen Ma, Yunsi Olyslager, Payal Thakkar, Lixia Pei, Christoph Heuck, Evangelos Terpos
Journal: Blood
Blood (2022) 140 (Supplement 1): 7292–7293.
https://doi.org/10.1182/blood-2022-163260
Published: 2022
Journal Articles

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection

Free
Mohamed A Badawi, Sheryl Coppola, Doerthe Eckert, Sathej Gopalakrishnan, Eva Doelger, Edyta Dobkowska, Shaji K Kumar, Weize Huang, Rajeev Menon, Ahmed Hamed Salem
Journal: Blood
Blood (2022) 140 (Supplement 1): 4281–4282.
https://doi.org/10.1182/blood-2022-166584
Published: 2022
Journal Articles

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

Free
Radhika Bansal, Sikander Ailawadhi, Jeremy T. Larsen, Morie A Gertz, Matthew A. Hathcock, David Dingli, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R. Hayman, Rahma M Warsame, Moritz Binder, Ricardo D Parrondo, Rafael Fonseca, P. Leif Bergsagel, Shaji K Kumar, Yi Lin
Journal: Blood
Blood (2022) 140 (Supplement 1): 1862–1864.
https://doi.org/10.1182/blood-2022-166662
Published: 2022
Journal Articles

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Free
David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F. Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J. Costa, Jonathan L. Kaufman, Nizar J. Bahlis, Shaji K Kumar, Jeremy A. Ross, P.K. Epling-Burnette
Journal: Blood
Blood (2022) 140 (Supplement 1): 4242–4244.
https://doi.org/10.1182/blood-2022-160195
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Free
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide

Free
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K. Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A. Gertz, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 9998–9999.
https://doi.org/10.1182/blood-2022-160368
Published: 2022
Journal Articles

Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

Free
Radhika Bansal, Jonas Paludo, Matthew A. Hathcock, Megan T Spychalla, Arushi Khurana, Paul J. Hampel, Urshila Durani, Hassan B. Alkhateeb, David Dingli, Suzanne R. Hayman, Prashant Kapoor, Yucai Wang, Saad S. Kenderian, Moritz Binder, Taxiarchis Kourelis, Shaji K Kumar, Mithun V. Shah, Rahma M Warsame, N. Nora Bennani, Morie A Gertz, Patrick B. Johnston, Stephen M. Ansell, Mustaqeem A. Siddiqui, Yi Lin
Journal: Blood
Blood (2022) 140 (Supplement 1): 2399–2401.
https://doi.org/10.1182/blood-2022-167187
Published: 2022